Search

• GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO

  Media

  The data reflects our commitment to strengthening our oncology pipeline across immuno-oncology, synthetic lethality & oncology cell therapy

  https://www.gsk.com/en-gb/media/press-releases/gsk-to-highlight-continued-progress-in-oncology-pipeline-and-portfolio-with-data-presented-at-esmo/

  First published: 09 September 2021

• ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV

  Media

  ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study

  https://www.gsk.com/en-gb/media/press-releases/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-naïve-women-living-with-hiv/

  First published: 18 July 2016

• ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines

  Media

  ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines/

  First published: 01 June 2017

• Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare

  Media

  The Ministry of Health, Labour and Welfare has approved Juluca Combination Tablets for the maintenance treatment of (HIV-1) infection.

  https://www.gsk.com/en-gb/media/press-releases/juluca-dolutegravirrilpivirine-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/

  First published: 26 November 2018

• GSK to highlight the latest advances in cancer research from across its portfolio and pipeline at ESMO

  Media

  GSK will present new findings from across its diverse oncology portfolio and pipeline at the congress.

  https://www.gsk.com/en-gb/media/press-releases/gsk-to-highlight-the-latest-advances-in-cancer-research-from-across-its-portfolio-and-pipeline-at-esmo/

  First published: 01 September 2022

• PERLA phase II trial of Jemperli (dostarlimab) plus chemotherapy shows positive results in first-line metastatic non-squamous non-small cell lung cancer

  Media

  PERLA is the largest global head-to-head trial of PD-1 inhibitors in this patient population

  https://www.gsk.com/en-gb/media/press-releases/perla-phase-ii-trial-of-jemperli-dostarlimab-plus-chemotherapy-shows-positive-results-in-first-line-metastatic-non-squamous-non-small-cell-lung-cancer/

  First published: 07 December 2022

• Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

  Media

  Interim results from Part 1 of the RUBY clinical trial in primary advanced or recurrent endometrial cancer.

  https://www.gsk.com/en-gb/media/press-releases/phase-iii-ruby-clinical-trial-demonstrates-potential-of-jemperli-plus-chemotherapy-to-redefine-the-treatment-of-primary-advanced-or-recurrent-endometrial-cancer/

  First published: 27 March 2023

• Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia

  Media

  Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.

  https://www.gsk.com/en-gb/media/press-releases/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/

  First published: 15 September 2023

• GSK highlights new data in non-small cell lung cancer and endometrial cancer at the European Society for Medical Oncology (ESMO) Congress 2023, reinforcing potential of Jemperli (dostarlimab) as a backbone immuno-oncology therapy

  Media

  Late-breaking data from head-to-head PERLA trial shows favourable numerical trend in overall survival (OS) results

  https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-new-data-in-non-small-cell-lung-cancer-and-endometrial-cancer-at-esmo/

  First published: 17 October 2023

• New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence

  Media

  A new GSK survey shows a large number of adults do not understand how shingles may be triggered.

  https://www.gsk.com/en-gb/media/press-releases/new-global-survey-finds-widespread-misunderstandings-about-shingles-despite-its-lifetime-prevalence/

  First published: 30 November 2023